189 related articles for article (PubMed ID: 36717209)
1. Burosumab in management of X-linked hypophosphataemia: a retrospective cohort study of growth and serum phosphate levels.
Walker EYX; Lindsay TAJ; Allgrove J; Marlais M; Bockenhauer D; Hayes W
Arch Dis Child; 2023 May; 108(5):379-384. PubMed ID: 36717209
[TBL] [Abstract][Full Text] [Related]
2. Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia.
Linglart A; Imel EA; Whyte MP; Portale AA; Högler W; Boot AM; Padidela R; Van't Hoff W; Gottesman GS; Chen A; Skrinar A; Scott Roberts M; Carpenter TO
J Clin Endocrinol Metab; 2022 Feb; 107(3):813-824. PubMed ID: 34636899
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets.
Paloian NJ; Nemeth B; Sharafinski M; Modaff P; Steiner RD
Pediatr Nephrol; 2022 Nov; 37(11):2667-2677. PubMed ID: 35211790
[TBL] [Abstract][Full Text] [Related]
4. Sex differences of burosumab in children with X-linked hypophosphataemic rickets.
Filler G; Tremblay O; Chen E; Huang SSH; Stein R
Pediatr Nephrol; 2023 Sep; 38(9):3183-3187. PubMed ID: 36542147
[TBL] [Abstract][Full Text] [Related]
5. Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial.
Imel EA; Glorieux FH; Whyte MP; Munns CF; Ward LM; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Mao M; Chen CY; Skrinar A; San Martin J; Portale AA
Lancet; 2019 Jun; 393(10189):2416-2427. PubMed ID: 31104833
[TBL] [Abstract][Full Text] [Related]
6. Self-Administration of Burosumab in Children and Adults with X-Linked Hypophosphataemia in Two Open-Label, Single-Arm Clinical Studies.
Kubota T; Namba N; Tanaka H; Muroya K; Imanishi Y; Takeuchi Y; Kanematsu M; Sun W; Seino Y; Ozono K
Adv Ther; 2023 Apr; 40(4):1530-1545. PubMed ID: 36719566
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial.
Whyte MP; Carpenter TO; Gottesman GS; Mao M; Skrinar A; San Martin J; Imel EA
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):189-199. PubMed ID: 30638856
[TBL] [Abstract][Full Text] [Related]
8. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
[TBL] [Abstract][Full Text] [Related]
9. Clinical practice guidelines for paediatric X-linked hypophosphataemia in the era of burosumab.
Sandy JL; Simm PJ; Biggin A; Rodda CP; Wall CL; Siafarikas A; Munns CF
J Paediatr Child Health; 2022 May; 58(5):762-768. PubMed ID: 35426466
[TBL] [Abstract][Full Text] [Related]
10. Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.
Weber TJ; Imel EA; Carpenter TO; Peacock M; Portale AA; Hetzer J; Merritt JL; Insogna K
J Clin Endocrinol Metab; 2022 Dec; 108(1):155-165. PubMed ID: 36072994
[TBL] [Abstract][Full Text] [Related]
11. Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries.
Mughal MZ; Baroncelli GI; de Lucas-Collantes C; Linglart A; Magnolato A; Raimann A; Santos F; Schnabel D; Shaw N; Nilsson O
Front Endocrinol (Lausanne); 2022; 13():1034580. PubMed ID: 36798486
[TBL] [Abstract][Full Text] [Related]
12. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
[TBL] [Abstract][Full Text] [Related]
13. Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives.
Seefried L; Duplan MB; Briot K; Collins MT; Evans R; Florenzano P; Hawkins N; Javaid MK; Lachmann R; Ward LM
Front Endocrinol (Lausanne); 2023; 14():1211426. PubMed ID: 37547321
[TBL] [Abstract][Full Text] [Related]
14. Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description.
Brandi ML; Ariceta G; Beck-Nielsen SS; Boot AM; Briot K; de Lucas Collantes C; Emma F; Giannini S; Haffner D; Keen R; Levtchenko E; Mӓkitie O; Nilsson O; Schnabel D; Tripto-Shkolnik L; Zillikens MC; Liu J; Tudor A; Mughal MZ
Ther Adv Chronic Dis; 2022; 13():20406223221117471. PubMed ID: 36082134
[TBL] [Abstract][Full Text] [Related]
15. Management of patients with X-linked hypophosphatemic rickets during Covid-19 pandemic lockdown.
Baroncelli GI; Bertelloni S; Cosci O Di Coscio M; Tyutyusheva N; D'Elios S; Peroni D
J Pediatr Endocrinol Metab; 2021 Jul; 34(7):905-910. PubMed ID: 33887813
[TBL] [Abstract][Full Text] [Related]
16. Magnetic resonance imaging is a valuable tool to evaluate the therapeutic efficacy of burosumab in children with X-linked hypophosphatemia.
Zhukouskaya VV; Mannes I; Chaussain C; Kamenický P; Audrain C; Lambert AS; Nevoux J; Wicart P; Briot K; Di Rocco F; Trabado S; Prié D; Di Somma C; Colao A; Adamsbaum C; Rothenbuhler A; Linglart A
Eur J Endocrinol; 2021 Aug; 185(4):475-484. PubMed ID: 34292170
[TBL] [Abstract][Full Text] [Related]
17. X-linked hypophosphatemia and burosumab: Practical clinical points from the French experience.
Bacchetta J; Rothenbuhler A; Gueorguieva I; Kamenicky P; Salles JP; Briot K; Linglart A
Joint Bone Spine; 2021 Oct; 88(5):105208. PubMed ID: 34102329
[TBL] [Abstract][Full Text] [Related]
18. Burosumab for Pediatric X-Linked Hypophosphatemia.
Imel EA
Curr Osteoporos Rep; 2021 Jun; 19(3):271-277. PubMed ID: 33970403
[TBL] [Abstract][Full Text] [Related]
19. Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment.
Kamenicky P; Briot K; Brandi ML; Cohen-Solal M; Crowley RK; Keen R; Kolta S; Lachmann RH; Lecoq AL; Ralston SH; Walsh JS; Rylands AJ; Williams A; Sun W; Nixon A; Nixon M; Javaid MK
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36854566
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological management of X-linked hypophosphataemia.
Imel EA; White KE
Br J Clin Pharmacol; 2019 Jun; 85(6):1188-1198. PubMed ID: 30207609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
